Honoring its Oklahoma roots and global reach, Cytovance reflects on two decades of growth, innovation, and partnership as a trusted CDMO delivering large-scale strength with small-CDMO agility.
Antibody reduction is the spontaneous degradation of inter-chain disulfide bonds resulting in a build-up of partial related substances of an IgG in bioprocess streams. Join Aaron Martin, Associate Director of Analytical Development, for the live webinar on Tuesday, May 23, 2023 | 12pm EDT (US) | 11am CT (US).
Antibody Reduction in Bioprocessing
X-talk Read More »
Cytovance Biologics, a global leading contract development and manufacturing provider of microbial, mammalian and plasmid DNA services in clinical and commercial manufacturing will participate in the upcoming BIO International Convention 2022 in San Diego
Cytovance Biologics To Participate In BIO International Convention 2022 Read More »
Oklahoma City, OK. – October 18, 2019 – Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming Recent Advances in Fermentation Technology (#RAFT) Conference to be held October 29 – November 1, 2017 at the Hyatt Coconut Point, Bonita Springs (Ft. Myers), Florida.
Oklahoma City, OK. – August 28, 2019 –Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming Bioprocess International (BPI) Conference #BPIconf at the Boston Convention and Exhibition Center (BCEC) in Boston, MA on September 9-12, 2019.BPI is the largest bioprocessing event bringing
Cytovance® Biologics To Participate In Boston’s BioProcess International Convention Read More »